Novalis LifeSciences

BlueWhale Bio is a spinout from the University of Pennsylvania focused on advancing cell-based therapies through innovative manufacturing solutions. The company develops cell drugs aimed at addressing challenges in gene therapy manufacturing, particularly in the context of cancer treatment. By specializing in cell therapy, BlueWhale Bio seeks to enable patients to access effective cancer treatment plans, thereby contributing to the broader field of regenerative medicine and improving therapeutic outcomes for individuals battling cancer.

Flywheel.io is a cloud-based data management platform tailored for biomedical research and collaboration. Founded in 2012 and headquartered in Minneapolis, Minnesota, the company provides a suite of tools designed to enhance the workflow of scientists and researchers. Its platform supports medical imaging, scientific computation, and content management, enabling users to capture, manage, and analyze research data efficiently. By utilizing cloud scalability and automation, Flywheel facilitates collaborative research, machine learning applications, and multicenter studies, which help organizations streamline their research processes. The platform, featuring a modern web interface and extensible compute engine, aims to eliminate bottlenecks in innovation, allowing researchers to focus on scientific discovery rather than IT challenges.

Telesis Bio is a biotechnology company founded in 2013 and based in San Diego, USA. It specializes in synthetic biology, providing researchers with tools to design, create, and secure synthetic DNA and mRNA. The company focuses on enabling the rapid, accurate, and reproducible synthesis of high-quality synthetic genetic materials for various applications in synthetic biology. Telesis Bio manufactures and sells a range of laboratory equipment, including synthetic biology instruments and reagents, as well as offering related services. Its product lineup features the BioXp system, BioXp kits, and Benchtop reagents, alongside BioXp biofoundry services, all aimed at supporting innovative research and development in the field.

Animol Discovery is a biotechnology company focused on developing proprietary veterinary small molecules to address the medical needs of animals. Led by a team of experts with extensive experience in the animal health industry, Animol utilizes a unique technology platform that leverages DNA-encoded chemicals. This innovative approach allows for accelerated ultra-high throughput screening, enabling the simultaneous evaluation of target and anti-target activities. By streamlining the drug discovery process, Animol aims to deliver effective and innovative medicines tailored specifically for veterinary patients, ultimately improving treatment options available to pet owners.

Mercy BioAnalytics is a biotechnology company based in Natick, Massachusetts, founded in 2018 by Paul Blavin and Joseph Sedlak. The company focuses on improving cancer outcomes through early detection using a novel liquid biopsy assay platform. This platform analyzes tumor-derived extracellular vesicles, which are plentiful in blood and contain critical information about their parent cells. By leveraging these extracellular vesicles, Mercy BioAnalytics aims to enable the detection of various types of cancer at the earliest stages, thus improving the chances of successful treatment and patient survival.

LevitasBio specializes in cellular analytics through its innovative platform that employs magnetic levitation technology. This approach addresses the limitations of traditional cellular analysis by offering label-free and universal methods for studying high-value primary samples and sensitive cell types. The company's LeviCell platform enables scientists to purify cells and nuclei without the need for markers or modifications, allowing for the examination of biological signatures while preserving the integrity of the original samples. By facilitating a deeper and more accurate understanding of biological processes, LevitasBio aims to advance research in the life sciences and healthcare sectors.

eTheRNA Immunotherapies NV is a Belgium-based biotechnology company that specializes in the development of mRNA-based immunotherapies. Founded in 2013 and located in Niel, the company focuses on harnessing the immune system's dendritic cells to create treatments for melanoma, triple-negative breast cancer, and infectious diseases. eTheRNA has developed innovative TriMix technology that enhances the immune response, enabling patients to better combat these diseases. The company aims to be a leader in nucleic acid-based medicines, collaborating with partners to facilitate the creation of new drugs and improve patient outcomes. Additionally, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its mission.

Animol Discovery is a biotechnology company focused on developing proprietary veterinary small molecules to address the medical needs of animals. Led by a team of experts with extensive experience in the animal health industry, Animol utilizes a unique technology platform that leverages DNA-encoded chemicals. This innovative approach allows for accelerated ultra-high throughput screening, enabling the simultaneous evaluation of target and anti-target activities. By streamlining the drug discovery process, Animol aims to deliver effective and innovative medicines tailored specifically for veterinary patients, ultimately improving treatment options available to pet owners.

Enko Chem, Inc., established in 2017 and based in Woburn, Massachusetts, specializes in the discovery and development of small-molecule and novel products designed to protect crops from pests and diseases. The company's proprietary technology platform enables it to swiftly identify safe and cost-effective solutions, contributing to sustainable food production.

Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.

Sherlock Biosciences, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative molecular diagnostic solutions. The company utilizes advanced engineering biology tools, such as CRISPR and synthetic biology, to create diagnostic platforms capable of delivering accurate and rapid results. Its notable technologies include SHERLOCK, a method for detecting and quantifying specific genetic sequences, and INSPECTR, which is designed for versatile, easy-to-use diagnostics. Sherlock Biosciences aims to serve various applications, including precision oncology, infectious disease identification, food safety, at-home testing, and general disease detection. Founded in 2018, the company is committed to providing affordable diagnostics suitable for diverse settings, including those with low-resource environments.

Ori Biotech is a developer of a manufacturing platform focused on enhancing access to life-saving cell and gene therapies. The company offers a proprietary, flexible manufacturing solution designed to automate and standardize production processes, enabling therapeutic developers to progress from pre-clinical development to commercial-scale manufacturing. By integrating advanced hardware, software, data, and analytics, Ori Biotech's platform aims to increase throughput, improve quality, and reduce costs in the manufacturing of cell and gene therapies. This innovation facilitates the rapid commercialization of new treatments, ultimately benefiting patients who require personalized and effective therapeutic options.

SkylineDx specializes in developing and commercializing advanced diagnostic tests that leverage gene signature analysis. These tests aid healthcare professionals in making personalized treatment decisions by accurately identifying disease types or status, and predicting patients' responses to specific treatments.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on the agriculture industry through the development of biological products. Founded in 2012, AgBiome leverages its expertise in plant-associated microbes and modern genomics to create innovative solutions aimed at enhancing plant health, pest resistance, and crop yields. The company addresses critical agricultural challenges, including soil-borne diseases, insects, and nematodes, by offering fungicides and a platform that identifies and screens diverse microbial strains. AgBiome collaborates with prominent agricultural partners to accelerate discovery processes and broaden the reach of its sustainable products in global markets. With a dedicated team of over 85 employees and a state-of-the-art laboratory and greenhouse facility, AgBiome is committed to improving food production responsibly.

Modality.AI, Inc. is a healthcare technology company based in San Francisco, California, founded in 2018. It specializes in AI-powered solutions that enhance the efficiency of clinical trials for neurological and mental health therapies. The company's platform utilizes conversational AI to engage patients through naturalistic spoken interaction, allowing for continuous health assessments anytime and anywhere. By analyzing multimodal data, including audio-visual biomarkers, Modality.AI provides objective measures that correlate with clinical outcomes. This innovative approach enables pharmaceutical companies to conduct self-driven assessments and improve the monitoring of health conditions, ultimately facilitating more effective clinical trials.

Allurion Technologies, Inc. is a medical device company based in Natick, Massachusetts, founded in 2009. It specializes in developing innovative solutions for weight loss, particularly through its Allurion Program. This program features the Allurion Balloon, the world's first and only swallowable, procedure-less intragastric balloon designed to help overweight and obese patients achieve satiety, thereby reducing food intake and promoting weight loss. The balloon is administered to patients in the form of a capsule, allowing for a non-surgical, non-endoscopic, and anesthesia-free experience. In addition to the balloon, Allurion provides access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth services, all aimed at enhancing the weight loss journey.

Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is advancing a diverse pipeline that includes five clinical-stage investigational therapies and several preclinical compounds targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Key products under development include CVL-231, a positive allosteric modulator for schizophrenia; CVL-865, which is being tested for drug-resistant focal onset epilepsy and acute anxiety; and Tavapadon, a selective dopamine D1/D5 partial agonist for Parkinson's disease. Cerevel Therapeutics employs a unique approach that leverages expertise in neurocircuitry and receptor selectivity to address unmet medical needs in the field of neuroscience.

Enko Chem, Inc., established in 2017 and based in Woburn, Massachusetts, specializes in the discovery and development of small-molecule and novel products designed to protect crops from pests and diseases. The company's proprietary technology platform enables it to swiftly identify safe and cost-effective solutions, contributing to sustainable food production.

eTheRNA Immunotherapies NV is a Belgium-based biotechnology company that specializes in the development of mRNA-based immunotherapies. Founded in 2013 and located in Niel, the company focuses on harnessing the immune system's dendritic cells to create treatments for melanoma, triple-negative breast cancer, and infectious diseases. eTheRNA has developed innovative TriMix technology that enhances the immune response, enabling patients to better combat these diseases. The company aims to be a leader in nucleic acid-based medicines, collaborating with partners to facilitate the creation of new drugs and improve patient outcomes. Additionally, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its mission.

Biotalys is an agricultural technology company based in Ghent, Belgium, founded in 2013. The company specializes in researching and developing biopesticides designed to control pests and diseases on crops and harvested products. Biotalys employs its proprietary Agrobody technology platform to create protein-based biocontrol solutions that combine the effectiveness of chemical pesticides with the safety profile of biologicals. These solutions are suitable for both pre- and post-harvest applications, aiming to provide a more sustainable and safer food supply. The company's technology platform generates products that enable targeted delivery and retention of active ingredients to prevent and control weeds, pests, and diseases.

Allurion Technologies, Inc. is a medical device company based in Natick, Massachusetts, founded in 2009. It specializes in developing innovative solutions for weight loss, particularly through its Allurion Program. This program features the Allurion Balloon, the world's first and only swallowable, procedure-less intragastric balloon designed to help overweight and obese patients achieve satiety, thereby reducing food intake and promoting weight loss. The balloon is administered to patients in the form of a capsule, allowing for a non-surgical, non-endoscopic, and anesthesia-free experience. In addition to the balloon, Allurion provides access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth services, all aimed at enhancing the weight loss journey.